275 related articles for article (PubMed ID: 27586252)
21. The effects of vasopressin and its analogues on the liver and its disorders in the critically ill.
Asfar P; Radermacher P; Calès P; Oberti F
Curr Opin Crit Care; 2010 Apr; 16(2):148-52. PubMed ID: 20019608
[TBL] [Abstract][Full Text] [Related]
22. The vasopressin-induced excitation of hypoglossal and facial motoneurons in young rats is mediated by V1a but not V1b receptors, and is independent of intracellular calcium signalling.
Reymond-Marron I; Tribollet E; Raggenbass M
Eur J Neurosci; 2006 Sep; 24(6):1565-74. PubMed ID: 17004920
[TBL] [Abstract][Full Text] [Related]
23. Terlipressin in hepatorenal syndrome.
Mazur JE; Cooper TB; Dasta JF
Ann Pharmacother; 2011 Mar; 45(3):380-7. PubMed ID: 21386023
[TBL] [Abstract][Full Text] [Related]
24. Pharmacology, clinical efficacy and safety of terlipressin in esophageal varices bleeding, septic shock and hepatorenal syndrome.
Saner FH; Canbay A; Gerken G; Broelsch CE
Expert Rev Gastroenterol Hepatol; 2007 Dec; 1(2):207-17. PubMed ID: 19072411
[TBL] [Abstract][Full Text] [Related]
25. Terlipressin improves renal function in patients with cirrhosis and ascites without hepatorenal syndrome.
Krag A; Møller S; Henriksen JH; Holstein-Rathlou NH; Larsen FS; Bendtsen F
Hepatology; 2007 Dec; 46(6):1863-71. PubMed ID: 18027874
[TBL] [Abstract][Full Text] [Related]
26. Pharmacological characterization of FE 202158, a novel, potent, selective, and short-acting peptidic vasopressin V1a receptor full agonist for the treatment of vasodilatory hypotension.
Laporte R; Kohan A; Heitzmann J; Wisniewska H; Toy J; La E; Tariga H; Alagarsamy S; Ly B; Dykert J; Qi S; Wisniewski K; Galyean R; Croston G; Schteingart CD; Rivière PJ
J Pharmacol Exp Ther; 2011 Jun; 337(3):786-96. PubMed ID: 21411496
[TBL] [Abstract][Full Text] [Related]
27. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study.
Martín-Llahí M; Pépin MN; Guevara M; Díaz F; Torre A; Monescillo A; Soriano G; Terra C; Fábrega E; Arroyo V; Rodés J; Ginès P;
Gastroenterology; 2008 May; 134(5):1352-9. PubMed ID: 18471512
[TBL] [Abstract][Full Text] [Related]
28. Vasopressin 1a receptor partial agonism increases sodium excretion and reduces portal hypertension and ascites in cirrhotic rats.
Fernández-Varo G; Oró D; Cable EE; Reichenbach V; Carvajal S; de la Presa BG; Wiśniewski K; Ginés P; Harris G; Jiménez W
Hepatology; 2016 Jan; 63(1):207-16. PubMed ID: 26403564
[TBL] [Abstract][Full Text] [Related]
29. Mapping the binding site of arginine vasopressin to V1a and V1b vasopressin receptors.
Rodrigo J; Pena A; Murat B; Trueba M; Durroux T; Guillon G; Rognan D
Mol Endocrinol; 2007 Feb; 21(2):512-23. PubMed ID: 17082326
[TBL] [Abstract][Full Text] [Related]
30. Synthetic rat V1a vasopressin receptor fragments interfere with vasopressin binding via specific interaction with the receptor.
Mendre C; Dufour MN; Le Roux S; Seyer R; Guillou L; Calas B; Guillon G
J Biol Chem; 1997 Aug; 272(34):21027-36. PubMed ID: 9261104
[TBL] [Abstract][Full Text] [Related]
31. A Self-Assembling Lipidic Peptide and Selective Partial V2 Receptor Agonist Inhibits Urine Production.
Patel S; Volpe AB; Awwad S; Schätzlein AG; Haider S; Liu B; Uchegbu IF
Sci Rep; 2020 Apr; 10(1):7269. PubMed ID: 32350300
[TBL] [Abstract][Full Text] [Related]
32. Pharmacological characterization of F-180: a selective human V(1a) vasopressin receptor agonist of high affinity.
Andrés M; Trueba M; Guillon G
Br J Pharmacol; 2002 Apr; 135(7):1828-36. PubMed ID: 11934825
[TBL] [Abstract][Full Text] [Related]
33. Characterization of a novel, linear radioiodinated vasopressin antagonist: an excellent radioligand for vasopressin V1a receptors.
Barbeis C; Balestre MN; Jard S; Tribollet E; Arsenijevic Y; Dreifuss JJ; Bankowski K; Manning M; Chan WY; Schlosser SS
Neuroendocrinology; 1995 Aug; 62(2):135-46. PubMed ID: 8584113
[TBL] [Abstract][Full Text] [Related]
34. Pharmacological characterization of the human vasopressin receptor subtypes stably expressed in Chinese hamster ovary cells.
Tahara A; Saito M; Sugimoto T; Tomura Y; Wada K; Kusayama T; Tsukada J; Ishii N; Yatsu T; Uchida W; Tanaka A
Br J Pharmacol; 1998 Dec; 125(7):1463-70. PubMed ID: 9884074
[TBL] [Abstract][Full Text] [Related]
35. Vasopressin receptors from cultured mesangial cells resemble V1a type.
Jard S; Lombard C; Marie J; Devilliers G
Am J Physiol; 1987 Jul; 253(1 Pt 2):F41-9. PubMed ID: 2955705
[TBL] [Abstract][Full Text] [Related]
36. Potentiation of receptor-mediated cAMP production: role in the cross-talk between vasopressin V1a and V2 receptor transduction pathways.
Klingler C; Ancellin N; Barrault MB; Morel A; Corman B
Biochem J; 1998 Mar; 330 ( Pt 2)(Pt 2):1023-8. PubMed ID: 9480925
[TBL] [Abstract][Full Text] [Related]
37. Terlipressin in the management of liver disease.
Scheinberg AR; Martin P; Turkeltaub JA
Expert Opin Pharmacother; 2023; 24(15):1665-1671. PubMed ID: 37535437
[TBL] [Abstract][Full Text] [Related]
38. Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4.
Cheng LL; Stoev S; Manning M; Derick S; Pena A; Mimoun MB; Guillon G
J Med Chem; 2004 Apr; 47(9):2375-88. PubMed ID: 15084136
[TBL] [Abstract][Full Text] [Related]
39. Severe ischemic bowel necrosis caused by terlipressin during treatment of hepatorenal syndrome.
Kim HR; Lee YS; Yim HJ; Lee HJ; Ryu JY; Lee HJ; Yoon EL; Lee SJ; Hyun JJ; Jung SW; Koo JS; Choung RS; Lee SW; Choi JH
Clin Mol Hepatol; 2013 Dec; 19(4):417-20. PubMed ID: 24459647
[TBL] [Abstract][Full Text] [Related]
40. Effects of Selective Agonists of V1a, V2, and V1b Receptors on Sodium Transport in Rat Kidney.
Golosova DV; Karavashkina TA; Kutina AV; Marina AS; Natochin YV
Bull Exp Biol Med; 2016 Apr; 160(6):751-4. PubMed ID: 27165083
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
